The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Outcomes & healthcare utilization cost of patients with CLL refractory to BTK and BCL-2 inhibitors
Farrukh Awan, MD, UT Southwestern Medical Center, Dallas, TX, comments on the outcomes of patients with chronic lymphocytic leukemia (CLL) who are refractory to both BTK and BCL-2 inhibitors, discussing the healthcare utilization cost for these patients. Dr Awan explains that these patients have very few treatment options and are often retreated with BTK or BCL-2 inhibitors, which constitute the main expense associated with the care of these patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
